🔴 Humacyte is trading 6.3% down with no clear catalyst

Humacyte is trading 6.3% lower at $0.37 on October 13, 2026; no specific catalyst for the decline has been identified.

• Major U.S. indices are nearly flat, so broad-market weakness is not an evident explanation.
• On October 12, Humacyte said interim Phase 3 V012 results were accepted for presentation at ASN Kidney Week on October 22; no source connects the update to the decline.